Per 25 mcg/50 mcg/actuation MDI Salmeterol xinafoate 25 mcg, fluticasone propionate 50 mcg. Per 25 mcg/125 mcg/actuation MDI Salmeterol xinafoate 25 mcg, fluticasone propionate 125 mcg. Per 25 mcg/250 mcg/actuation MDI Salmeterol xinafoate 25 mcg, fluticasone propionate 250 mcg
Indications/Uses
Regular treatment of asthma where use of a combination product (long-acting β2-agonist & inhaled corticosteroid) is appropriate: Patients not adequately controlled w/ inhaled corticosteroids & as needed inhaled short acting β2-agonist; already adequately controlled on both inhaled corticosteroids & long-acting β2-agonist.
Pulmonary TB. Do not use to treat acute asthma symptoms for which fast & short-acting bronchodilator is required. Do not initiate during exacerbation or significantly worsening or acutely deteriorating asthma. Serious asthma-related adverse events & exacerbation; systemic effects (particularly childn & adolescents <16 yr at high doses) may occur. Deterioration of asthma control (may be sudden & progressive). Rarely, cardiac arrhythmias eg, supraventricular tachycardia, extrasystoles & atrial fibrillation & mild transient reduction in serum K (high doses) may occur. Possible development of pneumonia & other lower resp tract infections in patients w/ COPD. Reduce dose gradually once symptoms are controlled. Transferring intake from oral to inhalation. Prolonged treatment. Concomitant use w/ ritonavir; systemic ketoconazole or other potent CYP34 inhibitors. Black African patients or Afro-Caribbean ancestry. Pregnancy & lactation. Childn <4 yr.
R03AK06 - salmeterol and fluticasone ; Belongs to the class of adrenergics in combination with corticosteroids or other drugs, excluding anticholinergics. Used in the treatment of obstructive airway diseases.
Sign Out
